Bluebird bio stock surges after FDA lifts clinical hold on studies for sickle cell disease treatments
Shares of Bluebird bio Inc.
BLUE,
+0.72%
leapt 7.2% in premarket trading after the gene therapy company said the U.S. Food and Drug Administration (FDA) lifted the clinical holds on the company’s trials for its sickle cell disease (SCD) treatments. The…
